NEW YORK – The European Commission has approved gilteritinib (Astellas' Xospata) as a treatment for adult acute myeloid leukemia who have relapsed or refractory disease characterized by FLT3 mutations.
NEW YORK – The European Commission has approved gilteritinib (Astellas' Xospata) as a treatment for adult acute myeloid leukemia who have relapsed or refractory disease characterized by FLT3 mutations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.